Pfizer, Novartis lead USD 2 billion spending spree on gene therapy production Medical Dialogues Bureau28 Nov 2019 9:00 AM ISTNew Delhi: Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018,...
Aurobindo Pharma targets to achieve zero debt in three years sans Novartis deal Medical Dialogues Bureau26 Nov 2019 9:30 AM ISTIn September 2018, the USD three billion drug-maker, Aurobindo Pharma said its US subsidiary entered into an agreement to acquire commercial...
Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020 Medical Dialogues Bureau26 Nov 2019 9:28 AM ISTRoche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
Novartis gets U.S. nod for long-delayed copycat version of Amgen billion seller Neulasta drug Medical Dialogues Bureau6 Nov 2019 10:32 AM ISTZURICH: Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in...
Another delay in USD 2.1 million gene therapy Zolgensma data reporting, Novartis admits mistake Medical Dialogues Bureau3 Nov 2019 9:45 AM ISTThe USFDA on Wednesday placed a partial hold on a Novartis trial of the $2.1 million-per-patient gene therapy, Zolgensma after the company informed...
SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns Medical Dialogues Bureau31 Oct 2019 9:45 AM ISTNovartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings...
GSK ovarian cancer drug Zejula gets USFDA nod for wider use Medical Dialogues Bureau24 Oct 2019 10:00 AM ISTZejula was the lead compound of U.S. cancer specialist Tesaro, which GSK acquired for $5.1 billion last year. Zejula brought in sales of 57 million...
GSK to sell anti-rabies vaccines Rabipur, Encepur to Bavarian Nordic for USD 1.1 billion Medical Dialogues Bureau22 Oct 2019 10:00 AM ISTThe sale of GSK's anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, to the Denmark-based biotechnology...
Carcinogen in popular heartburn drug Zantac triggers safety review by European, US regulators Medical Dialogues Bureau14 Sept 2019 9:15 AM ISTValisure said in its report that it found the impurity in both Sanofi SA's branded Zantac as well as generic versions of the drug. But the FDA would...
Jubilant Life appoints Novartis Syed Kazmi as President, CEO of its new biotech startup Medical Dialogues Bureau11 Sept 2019 9:25 AM ISTDr Syed Kazmi joins from Novartis Pharmaceuticals Corporation where he was Vice President, Global Head of Business Development & Licensing for...
Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer Medical Dialogues Bureau8 Sept 2019 9:25 AM ISTNovartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small...
Cigna new plan to cover expensive gene therapies including Novartis Zolgensma, Luxturna Medical Dialogues Bureau8 Sept 2019 9:00 AM ISTThe first two gene therapies to be included in Cigna Corp's program are blindness therapy, Luxturna, and the most expensive drug in the world...
